Earlier cancer detection through patient-friendly blood tests.
Savicell harnesses the immune system’s metabolic response to reveal disease-associated signatures earlier.
Initial clinical focus: lung cancer. For research and development communication; availability and claims are jurisdiction-dependent.
LDCT screening can identify lung cancer earlier—often as small pulmonary nodules. Savicell’s first indication focuses on the next clinical question: adding biological information when an indeterminate pulmonary nodule has already been identified by imaging.
LDCT screening brings suspicious findings into the diagnostic pathway sooner—often when pulmonary nodules are still small and potentially more treatable.
Reported 5-year relative survival differs sharply when lung cancer is found while localized versus after distant spread.
LDCT screening helps bring suspicious findings into the diagnostic pathway earlier—often when pulmonary nodules are still small and potentially more treatable.
When imaging identifies an indeterminate pulmonary nodule, additional biological information may help distinguish cancer-associated from benign findings and reduce uncertainty in the next step.
Savicell has developed a patient-friendly blood test that measures functional immune responses to provide additional biological information for the evaluation of indeterminate pulmonary nodules identified by imaging.
The goal: help differentiate cancer-associated from benign nodule patterns and reduce unnecessary invasive and expensive diagnostic work-ups and short-term follow-up imaging.
See the lung-cancer pathway →Following the confirmation indication, Savicell plans to extend the same immune-intelligence platform toward blood-based screening in high-risk populations—moving the technology further upstream in the early-detection pathway.
Clinical statistics shown are contextual background figures and are not Savicell performance claims. Savicell’s screening application is a planned future development path and would require appropriate clinical validation.
A news report followed Savicell’s laboratory workflow and the story of a study participant whose lung cancer was detected during testing. The report described the finding as helping save his life.
Inside the laboratorySee Savicell’s real wet-lab workflow, equipment and team in action.
The science in actionFollow the journey from a blood sample to a measurable immune-cell response.
A real study storyA news report follows the story of a participant whose lung cancer was detected during the study.
Accessibility: English subtitles are embedded in the video.
Note: The video contains burned-in English captions. The text below is a concise content summary rather than a verbatim transcript.
The news feature introduces Savicell's blood-based Liquid ImmunoBiopsy™ approach and follows the laboratory process used to evaluate immune-cell metabolic responses.
Clinical experts discuss why early lung-cancer detection matters and describe the challenge of identifying disease when tumor-derived material may still be limited.
The report shows blood collection, laboratory sample handling, immune-cell preparation, assay processing and instrumental measurement inside Savicell's laboratory.
The feature also follows a study participant whose test produced a suspicious result during the study and describes the subsequent lung-cancer finding as having helped save his life.
The scientific concept presented is that disease can alter the functional response of immune cells, creating a measurable pattern that can be analyzed as a disease-associated signature.
Savicell captures dynamic metabolic responses to disease-associated stimuli, revealing functional immune signatures.
Don’t wait for the tumor signal. Read the immune response.
Concept visualization. Clinical performance depends on the specific indication, study population and validated use case.
Savicell is built on a simple idea: when immune T cells respond to a relevant challenge, they reprogram how they produce and use energy. Savicell measures that functional metabolic response.
Resting and activated T cells operate in different metabolic states. Following immune activation, T cells increase glycolytic metabolism to support rapid energy demand, proliferation and effector function.
Recognition of a disease-associated antigen can rapidly increase glycolytic metabolism to support immune activation.
This metabolic reprogramming provides the energy and biosynthetic resources required for proliferation and effector function.
Savicell measures stimulus-induced metabolic changes in living immune cells to reveal disease-associated functional signatures.
Illustrative chart of T-cell metabolic-state transitions from resting through activation to memory state.
Controlled immune stimulation → metabolic change → measurable profile → analytical classification.
A standardized wet-lab workflow captures a functional immune-cell response and connects it to Savicell's centralized analytics.
A standardized, scalable laboratory workflow that captures the metabolic response of immune cells and translates it into an early cancer detection signature.
A standard blood draw.
PBMCs are isolated and prepared.
Cells are exposed to disease-associated stimulants in a standardized multi-well assay.
Metabolic response is measured.
Response patterns are analyzed in our centralized pipeline to generate a disease signature.
Immune cells are exposed to disease-associated stimulants in a standardized multi-well assay.
The metabolic response is measured using a standard plate reader, generating a high-dimensional signature of immune cell function.
Response patterns are analyzed in our centralized analytics pipeline to generate an early cancer detection signature.
Illustrative workflow visualization. The exact assay configuration and analytical workflow depend on the validated use case.
A standard blood draw.
PBMCs are isolated and prepared for the assay.
Immune cells are exposed to disease-associated stimulants in a standardized multi-well metabolic assay.
The metabolic response is measured using laboratory instrumentation.
Savicell's proprietary algorithms and AI models analyze immune-response patterns to generate a disease signature.
Illustrative workflow. The exact assay configuration and analytical workflow depend on the validated use case.
A standardized, scalable laboratory workflow that captures the metabolic response of immune cells and translates it into an early cancer detection signature.
A standard blood draw.
PBMCs are isolated and prepared for the assay.
Immune cells are exposed to disease-associated stimulants in a standardized multi-well metabolic assay.
The metabolic response is measured using laboratory instrumentation.
Savicell's proprietary algorithms and AI models analyze immune-response patterns to generate a disease signature.
Illustrative workflow. The exact assay configuration and analytical workflow depend on the validated use case.
Savicell’s lung-cancer program has been evaluated in peer-reviewed clinical research. Performance figures are shown together with the publication, study context and cited dataset.
A novel, accurate, and non-invasive liquid biopsy test to measure cellular immune responses as a tool to diagnose early-stage lung cancer: a clinical trials study
Shai S. et al. Respiratory Research 24, 52. DOI: 10.1186/s12931-023-02358-w
Clinical performance varies by study design, population and intended use. Published results are not presented as a claim of commercial availability or performance in every setting.
Indeterminate pulmonary nodules are common, while many are ultimately benign. Savicell is developing a patient-friendly blood test intended to add biological insight to the clinical workup.
Illustrative clinical workflow; not a substitute for standard-of-care diagnostic evaluation.
An indeterminate pulmonary nodule is identified by imaging.
A standard blood draw provides the sample for the immune-response assay.
Immune cells are stimulated and their metabolic response is measured.
Savicell's proprietary algorithms and AI models analyze the immune-response pattern to generate a disease-associated signature.
The result is designed to add biological information to the next clinical step.
Illustrative workflow; not a substitute for standard-of-care diagnostic evaluation.
Different disease states can be associated with distinct immune-cell metabolic signatures, creating a biological basis for a broad diagnostic platform beyond a single disease.
Published immunometabolism research describes a continuum of immune-cell metabolic states across disease biology — from cancer and chronic infectious disease to metabolic and autoimmune disorders.
Savicell’s platform is designed to measure disease-associated changes in immune-cell metabolic activity after controlled stimulation and analyze the resulting functional response pattern.
Each additional indication requires dedicated clinical development and validation.
Source: Bantug G.R., Galluzzi L., Kroemer G., Hess C. The spectrum of T cell metabolism in health and disease. Nature Reviews Immunology. doi:10.1038/nri.2017.9. The chart is presented as a biological framework and does not represent validated Savicell performance across all listed diseases.
A non-invasive blood-test platform that translates functional immune responses into disease-associated signatures.
Building on the broader biology above, the same core workflow can support development of disease-specific signatures and multiple clinical applications.
Pipeline applications shown are development concepts and are subject to clinical validation and regulatory review.
Develop disease-specific signatures intended to identify clinically meaningful immune signals earlier.
Potential longitudinal use after treatment to track changes in disease-associated immune response.
Potential repeated measurement of functional immune-response patterns over time.
Development concept for immune-readiness and response stratification.
A shared analytical platform with separately developed and validated disease signatures.
Pipeline applications are development concepts and require dedicated clinical validation and regulatory review.
Wet-lab execution can be standardized across qualified partner laboratories, supported by Savicell’s centralized analytical platform, software, algorithms and core know-how.
Illustrative operating model. Final responsibilities, reporting and regulatory pathways depend on the market and partner arrangement.
Patient samples are collected at qualified partner sites.
Sample processing and PBMC preparation follow Savicell-controlled procedures and quality requirements.
Analytical software, algorithms and disease-signature interpretation remain centralized.
A standardized result is returned within the applicable clinical and regulatory framework.
Illustrative operating model. Final responsibilities and regulatory pathways depend on the market and partner arrangement.
Recent clinical, intellectual-property and company milestones. Explore the full archive for additional updates.
European Patent No. 3673267 and Canadian Patent No. 3,073,254 further expand Savicell’s international IP portfolio.
U.S. continuation Patent No. 12,306,188 and Israel Patent No. 272810 were added to Savicell’s patent estate.
The 2004 Nobel laureate in Chemistry and Distinguished Research Professor at the Technion joined Savicell’s Advisory Board.
Savicell brings together operating, scientific, quality and regulatory experience to translate immune-response biology into a scalable diagnostic platform.
Meet the full leadership & advisory team →Savicell is developing Liquid ImmunoBiopsy™, a blood-based platform that measures disease-associated immune metabolic responses. The company’s initial commercial focus is lung cancer, supported by published clinical research and a growing translational development program.
Different partners need different information. Start with the path that best matches your interest.
Explore partner-lab deployment, validation, implementation and commercial collaboration.
Discuss a partnershipDiscuss clinical research, validation programs, translational studies and new disease signatures.
Start a scientific conversationReview company information, platform strategy and investor-relations materials.
Investor relationsGeneral inquiries: info@savicell.com
Send a short note and the appropriate Savicell contact can follow up. Please do not submit medical records or sensitive health information through this form.
info@savicell.com
